TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Targeted Cell Phone Intervention to Improve Patient Access to Care and Drug Adherence in Patients Taking Antiretroviral (ARV) Medications in Kenya
Brief Summary: A clinical study to evaluate the use of cell phones to support drug adherence and follow-up of patients taking antiretroviral therapy (ART) for treatment of HIV. The intervention involves health-care providers sending regular short-message-service (SMS) text messages to patients and following up their responses. The hypothesis is that the cell phone intervention will improve ART adherence and health outcomes compared with the current standard of care.


Options:
A: Arm Label: Weekly SMS, brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Weekly SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Intervention Type: BEHAVIORAL; Name: Short Message Services to Support ARV therapy adherence; Assigned to Arm(s): Control Group, Daily SMS, Brief message, Daily SMS, Long Message, Weekly SMS, Long Message, Weekly SMS, brief message
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
D: Arm Label: 1 Standard Care (SC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Standard Care + Educational (SCE); Type: OTHER; Interventions: Behavioral: educational instruction in clinic | Arm Label: 3 Standard Care + Educational + Phone Calls (SCEP); Type: OTHER; Interventions: Behavioral: educational instruction and phone follow-up | Intervention Type: BEHAVIORAL; Name: educational instruction and phone follow-up; Assigned to Arm(s): 3 Standard Care + Educational + Phone Calls (SCEP) | Intervention Type: BEHAVIORAL; Name: educational instruction in clinic; Assigned to Arm(s): 2 Standard Care + Educational (SCE)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Targeted Cell Phone Intervention to Improve Patient Access to Care and Drug Adherence in Patients Taking Antiretroviral (ARV) Medications in Kenya
Brief Summary: A clinical study to evaluate the use of cell phones to support drug adherence and follow-up of patients taking antiretroviral therapy (ART) for treatment of HIV. The intervention involves health-care providers sending regular short-message-service (SMS) text messages to patients and following up their responses. The hypothesis is that the cell phone intervention will improve ART adherence and health outcomes compared with the current standard of care.


Options:
A: Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Arm Label: Informational SMS-text; Type: EXPERIMENTAL; Interventions: Behavioral: Informational SMS-text, Behavioral: Enhanced usual care | Arm Label: Interactive SMS-text; Type: EXPERIMENTAL; Interventions: Behavioral: Informational SMS-text, Behavioral: Interactive SMS-text, Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Informational SMS-text; Assigned to Arm(s): Informational SMS-text, Interactive SMS-text | Intervention Type: BEHAVIORAL; Name: Interactive SMS-text; Assigned to Arm(s): Interactive SMS-text | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care, Informational SMS-text, Interactive SMS-text
B: Arm Label: A, 1, I; Type: EXPERIMENTAL; Interventions: Device: Home blood pressure tele-management system. | Arm Label: A, 2, I; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care. | Intervention Type: DEVICE; Name: Home blood pressure tele-management system.; Assigned to Arm(s): A, 1, I | Intervention Type: OTHER; Name: Usual care.; Assigned to Arm(s): A, 2, I
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Educational Intervention | Arm Label: No Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational Intervention; Assigned to Arm(s): Intervention Group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Targeted Cell Phone Intervention to Improve Patient Access to Care and Drug Adherence in Patients Taking Antiretroviral (ARV) Medications in Kenya
Brief Summary: A clinical study to evaluate the use of cell phones to support drug adherence and follow-up of patients taking antiretroviral therapy (ART) for treatment of HIV. The intervention involves health-care providers sending regular short-message-service (SMS) text messages to patients and following up their responses. The hypothesis is that the cell phone intervention will improve ART adherence and health outcomes compared with the current standard of care.


Options:
A: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care
B: Intervention Type: BEHAVIORAL; Name: Comprehensive pharmacy care program; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: carvedilol; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Progesterone to Reduce Preterm Birth
Brief Summary: Preterm birth is the most common and costly complication in obstetrics. It complicates up to 11 % of all pregnancies and it is responsible for 70% of sick babies. Recently two studies have shown that giving progesterone (a normal hormone made by the ovaries) prolongs gestation in women who have had a preterm birth in an earlier pregnancy (and therefore are at risk for another early delivery). There are other studies that show that this technique of giving a weekly shot of progesterone does not prevent preterm birth. In addition, There are other groups of patients who are at very high risk for preterm birth which have not been studied. They include: 1.) Cervical cerclage (a stitch in the mouth of the womb); 2.) Multifetal gestation (twins, triplets, etc.); 3.) Women with preterm (\<34 weeks) rupture of the membranes; 4.) Women with preterm labor during the current pregnancy with intact membranes who have been tocolyzed (have their labor stopped and are getting ready to go home). We purpose to give weekly shots of progesterone or a placebo in a randomized fashion to women in the first group who are at risk for preterm delivery due to an early birth in a previous pregnancy as well as the other four groups listed. If progesterone given weekly is successful at preventing early delivery as compared to the placebo group then great benefit for these women as well as future pregnancies would be accrued.


Options:
A: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone (OHP17) | Intervention Type: DRUG; Name: Progesterone (OHP17); Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate (17P); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Progesterone to Reduce Preterm Birth
Brief Summary: Preterm birth is the most common and costly complication in obstetrics. It complicates up to 11 % of all pregnancies and it is responsible for 70% of sick babies. Recently two studies have shown that giving progesterone (a normal hormone made by the ovaries) prolongs gestation in women who have had a preterm birth in an earlier pregnancy (and therefore are at risk for another early delivery). There are other studies that show that this technique of giving a weekly shot of progesterone does not prevent preterm birth. In addition, There are other groups of patients who are at very high risk for preterm birth which have not been studied. They include: 1.) Cervical cerclage (a stitch in the mouth of the womb); 2.) Multifetal gestation (twins, triplets, etc.); 3.) Women with preterm (\<34 weeks) rupture of the membranes; 4.) Women with preterm labor during the current pregnancy with intact membranes who have been tocolyzed (have their labor stopped and are getting ready to go home). We purpose to give weekly shots of progesterone or a placebo in a randomized fashion to women in the first group who are at risk for preterm delivery due to an early birth in a previous pregnancy as well as the other four groups listed. If progesterone given weekly is successful at preventing early delivery as compared to the placebo group then great benefit for these women as well as future pregnancies would be accrued.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone (OHP17) | Intervention Type: DRUG; Name: Progesterone (OHP17); Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo
D: Intervention Type: DRUG; Name: Micronised progesterone (Utrogestan); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Progesterone to Reduce Preterm Birth
Brief Summary: Preterm birth is the most common and costly complication in obstetrics. It complicates up to 11 % of all pregnancies and it is responsible for 70% of sick babies. Recently two studies have shown that giving progesterone (a normal hormone made by the ovaries) prolongs gestation in women who have had a preterm birth in an earlier pregnancy (and therefore are at risk for another early delivery). There are other studies that show that this technique of giving a weekly shot of progesterone does not prevent preterm birth. In addition, There are other groups of patients who are at very high risk for preterm birth which have not been studied. They include: 1.) Cervical cerclage (a stitch in the mouth of the womb); 2.) Multifetal gestation (twins, triplets, etc.); 3.) Women with preterm (\<34 weeks) rupture of the membranes; 4.) Women with preterm labor during the current pregnancy with intact membranes who have been tocolyzed (have their labor stopped and are getting ready to go home). We purpose to give weekly shots of progesterone or a placebo in a randomized fashion to women in the first group who are at risk for preterm delivery due to an early birth in a previous pregnancy as well as the other four groups listed. If progesterone given weekly is successful at preventing early delivery as compared to the placebo group then great benefit for these women as well as future pregnancies would be accrued.


Options:
A: Intervention Type: DRUG; Name: Micronised progesterone (Utrogestan); Assigned to Arm(s): N/A
B: Arm Label: 1 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Progesterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Progesterone (OHP17) | Intervention Type: DRUG; Name: Progesterone (OHP17); Assigned to Arm(s): Progesterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 Placebo
C: Arm Label: 17 alpha-hydroxyprogesterone caproate; Type: ACTIVE_COMPARATOR; Interventions: Drug: 17 alpha-hydroxyprogesterone caproate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Oil | Intervention Type: DRUG; Name: 17 alpha-hydroxyprogesterone caproate; Assigned to Arm(s): 17 alpha-hydroxyprogesterone caproate | Intervention Type: OTHER; Name: Placebo Oil; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: 8% progesterone vaginal gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Vaginal Gel | Intervention Type: DRUG; Name: 8% progesterone vaginal gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Vaginal Gel; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis.
Brief Summary: Cryptococcal Meningitis continues to be one of the most devastating AIDS defining illness in sub-Saharan Africa. Despite the availability of azoles such as fluconazole for treatment, mortality remains high with some studies showing 100% mortality. The investigators designed a study to determine if timing of the initiation of antiretroviral therapy (ART) in patients with cryptococcal meningitis and HIV would improve survival. The investigators hypothesis was that early initiation of ART result in improved mortality for patients with HIV and cryptococcal meningitis.


Options:
A: Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Sertraline 400mg; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Sertraline 400mg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2
C: Arm Label: Early antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Other: Early antiretroviral therapy | Arm Label: Standard antiretroviral therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early antiretroviral therapy; Assigned to Arm(s): Early antiretroviral therapy
D: Arm Label: Standard Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amphotericin B, Drug: Fluconazole | Arm Label: Fluconazole Low Dose; Type: EXPERIMENTAL; Interventions: Drug: Amphotericin B, Drug: Fluconazole | Arm Label: Fluconazole High Dose; Type: EXPERIMENTAL; Interventions: Drug: Amphotericin B, Drug: Fluconazole | Intervention Type: DRUG; Name: Amphotericin B; Assigned to Arm(s): Fluconazole High Dose, Fluconazole Low Dose, Standard Therapy | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): Fluconazole High Dose, Fluconazole Low Dose, Standard Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis.
Brief Summary: Cryptococcal Meningitis continues to be one of the most devastating AIDS defining illness in sub-Saharan Africa. Despite the availability of azoles such as fluconazole for treatment, mortality remains high with some studies showing 100% mortality. The investigators designed a study to determine if timing of the initiation of antiretroviral therapy (ART) in patients with cryptococcal meningitis and HIV would improve survival. The investigators hypothesis was that early initiation of ART result in improved mortality for patients with HIV and cryptococcal meningitis.


Options:
A: Arm Label: Earlier HIV Therapy; Type: EXPERIMENTAL; Interventions: Drug: efavirenz, Biological: nucleoside | Arm Label: Deferred HIV Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: efavirenz, Biological: nucleoside | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy | Intervention Type: BIOLOGICAL; Name: nucleoside; Assigned to Arm(s): Deferred HIV Therapy, Earlier HIV Therapy
B: Arm Label: Early ART; Type: EXPERIMENTAL; Interventions: Drug: All licensed antiretroviral medications | Arm Label: Deferred ART; Type: ACTIVE_COMPARATOR; Interventions: Drug: All licensed antiretroviral medications | Intervention Type: DRUG; Name: All licensed antiretroviral medications; Assigned to Arm(s): Deferred ART, Early ART
C: Intervention Type: DRUG; Name: Emtricitabine/tenofovir disoproxil fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis.
Brief Summary: Cryptococcal Meningitis continues to be one of the most devastating AIDS defining illness in sub-Saharan Africa. Despite the availability of azoles such as fluconazole for treatment, mortality remains high with some studies showing 100% mortality. The investigators designed a study to determine if timing of the initiation of antiretroviral therapy (ART) in patients with cryptococcal meningitis and HIV would improve survival. The investigators hypothesis was that early initiation of ART result in improved mortality for patients with HIV and cryptococcal meningitis.


Options:
A: Arm Label: Same-Day ART Group; Type: EXPERIMENTAL; Interventions: Other: Same-Day HIV testing and ART initiation | Arm Label: Standard ART Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard ART Initiation | Arm Label: Sub-Study - Same-Day ART, CD4>500; Type: EXPERIMENTAL; Interventions: Other: Sub-Study: Same-Day ART, CD4 Count >500 | Arm Label: Sub-Study - Pre-ART Care, CD4>500; Type: ACTIVE_COMPARATOR; Interventions: Other: Sub-Study: Standard Pre-ART Care, CD4 Count >500 | Intervention Type: OTHER; Name: Same-Day HIV testing and ART initiation; Assigned to Arm(s): Same-Day ART Group | Intervention Type: OTHER; Name: Standard ART Initiation; Assigned to Arm(s): Standard ART Group | Intervention Type: OTHER; Name: Sub-Study: Same-Day ART, CD4 Count >500; Assigned to Arm(s): Sub-Study - Same-Day ART, CD4>500 | Intervention Type: OTHER; Name: Sub-Study: Standard Pre-ART Care, CD4 Count >500; Assigned to Arm(s): Sub-Study - Pre-ART Care, CD4>500
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Efavirenz, Drug: Lamivudine/Zidovudine | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz, Drug: Lamivudine/Zidovudine | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Lamivudine/Zidovudine; Assigned to Arm(s): A, B
D: Arm Label: MJAP Clinics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: START | Arm Label: MJAP Clinics Pre-Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: START; Assigned to Arm(s): MJAP Clinics Intervention

Answer: B